Cannabis and Aging

NCT ID: NCT05084105

Last Updated: 2022-05-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-02-01

Study Completion Date

2021-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

With increased availability and use of cannabis by older adults aged ≥ 50 years, a rigorous evaluation of the benefits and risks of cannabis use in these individuals is necessary. Our proposed project will investigate whether older adults who initiate cannabis use after the age of 50 are at an increased risk of fall and what are the underlying mechanisms. We will measure motor and cognitive function in older cannabis users and nonusers and we will use positron emission tomography to determine brain activity and how it is associated with fall risk.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The prevalence of cannabis use has increased significantly in recent years among US adults aged 50 years and older. With increased availability and use of cannabis by older adults, a rigorous evaluation of the benefits and risks of cannabis use in these individuals is necessary. Aging is characterized by physiological and social changes that make older adults vulnerable to chronic disease and geriatric conditions, including cognitive impairment and falls. Unintentional falls are a common event for older adults and a major cause of morbidity and mortality linked with a decline in functional status and disability. Moreover, falls and cognitive impairment are a "well-known couple"; as older adults with moderate to severe cognitive impairment have a higher risk of falls, with an annual incidence of around 60-80%, which is twice the rate of cognitively normal older adults. Impaired cognitive function is an effect of cannabis use, and there is increasing evidence that those effects may persist later in life. Therefore, the physiological effects of chronic cannabis use may further increase falls in older adults via alterations in gait and cognition. Studies have shown reduced neural activity in the frontal brain networks and associations with increased fear of falling in older adults. It is also known that in regular cannabis users, the effects of cannabis may have an impact on cognitive-motor skills and brain mechanisms that modulate coordinated movement. The goal of this application is to investigate the neural correlates of fall risk and cognitive and motor function in individuals who initiate drug use after the age of 50. We will use FDG-PET to determine brain activity. Fall risk and cognitive/motor function will be assessed with the measures from the NIH Toolbox and a fall risk model. Our central hypothesis is that older chronic cannabis users are at a higher fall risk than older non-users, which is associated with reduced cerebral FDG uptake. These results are expected to provide critical and timely data to the public and health professionals regarding the effects of self-directed cannabis use on increased fall risk and if clinicians need to assess cannabis use when determining fall risk and deciding prevention strategies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cannabis Use

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cannabis Group

A total of 30 older (age 50-80 years) men and women who are using cannabis.

No interventions assigned to this group

Control Group

A total of 30 older (age 50-80 years) men and women who are not using cannabis.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 50-80 years
* Healthy enough to complete the protocol based on information obtained from a clinical exam and past medical history, such as cardiovascular diseases.
* Comprehension of the protocol as indicated by an ability to respond to questions about the study after reading the consent form.
* Able to use and be contacted by telephone.
* Able to speak, read, and understand English, and complete a questionnaire in English

Exclusion Criteria

* Presence of pacemakers, aneurysm clips, artificial heart valves, metallic prostheses
* Pregnancy
* History of significant traumatic brain injury
* Unable to lie flat for the study imaging
Minimum Eligible Age

50 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Thorsten Rudroff

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Thorsten Rudroff

Associate Professor

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Health and Human Physiology

Iowa City, Iowa, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

201909808

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effects of Cannabidiol in Alcohol Use Disorder
NCT03252756 COMPLETED PHASE1/PHASE2
Alcohol Use Disorder and Cannabidiol
NCT05613608 RECRUITING PHASE2/PHASE3
UH3 Varenicline for Cannabis Use Disorder
NCT03980561 COMPLETED PHASE2